Metformin (generic), Glucophage News

Metformin, a Type II diabetic treatment drug, which inhibits transcription of gluconeogenesis genes, has recently been shown to lower the risk of some diabetes-related tumors, including breast cancer.

OBJECTIVE Study the effects of exenatide plus rosiglitazone on I2-cell function and insulin sensitivity using hyperglycemic and euglycemic insulin clamp techniques in participants with type 2 diabetes on metformin.RESEARCH DESIGN AND METHODS In this 20-week, randomized, open-label, multicenter study, participants continued their metformin regimen ... (more)

On the heels of its recent approval of the injectable drug Bydureon, the US Food and Drug Administration has approved linagliptin/metformin hydrochloride , an oral medicine for Type 2 diabetes manufactured by Boehringer Ingelheim Pharmaceuticals, Inc., and Eli Lilly and Company.

Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial by: Jolien de Jager , Adriaan Kooy , Philippe Lehert , Michiel G. WulffelA© , Jan van der Kolk , DaniA l Bets , Joop Verburg , Ab J. M. Donker , Coen D. A. Stehouwer To insert individual citation into a ... (more)

This, of course, is a topic to which everyone can relate. The only baby boomers who don't have something to moan and groan about at this stage are the ones who are no longer with us.

The American College of Physicians recommends that metformin be the first medication used to treat type 2 diabetes when diet, exercise and weight loss do not improve blood sugar, according to a new clinical practice guideline.

At the same time, some migraine medicines can cause birth defects, so medical experts advise pregnant women not to use them.

ACP also recommends that clinicians add a second drug to metformin when treatment with metformin and lifestyle changes fail to control blood sugar levels.

Recently, several more combination diabetes pills have become available, and I think I ought to update my previous essay on "Combination pills for type 2 diabetes" to include the new combo pills.

MONDAY, Feb. 6 -- When it comes to the treatment of type 2 diabetes, the first line of defense is lifestyle changes such as losing weight and exercising more often.

Depomed, Inc. Announces FDA Approval of Merck & Co., Inc. 's JANUMET XR That Accesses Depomed Patents Licensed to Merck MENLO PARK, Calif., Feb.

Creating a home safety checklist can help seniors prevent injuries and let them prepare if they happen to fall or hurt themselves.

Depomed, Inc. today announced that Merck disclosed on February 2, 2012 that the U.S. Food and Drug Administration approved JANUMETA XR tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of JANUVIAA , with extended-release metformin.

WHAT IT MEANS AND WHY IT'S IMPORTANT - For all the fears about the patent cliff, at least one disease state seems to be on the up-and-up in terms of new drug development and new products.

Drugmaker Merck & Co Inc. said Thursday it received U.S. approval for an extended-release version of its diabetes drug Janumet designed to be taken once a day, instead of twice a day.

NEW YORK -- When good earnings come about as the result of cost cuts, exhilaration is woefully misplaced.

Become familiar with your state's laws about distracted driving, and educate your teen about the legal consequences of distracted driving.

According to a recent study report published in the Annals of Internal Medicine , not all clinical practice guidelines on the use of oral medications for type 2 diabetes are consistent with the findings of a systematic review of the available scientific evidence that was funded by the Agency for Healthcare Research and Quality .

RIDGEFIELD, Conn., and INDIANAPOLIS, Jan. 30, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.

TUESDAY, Jan. 31 -- A new Swiss-American study indicates that long-term use of the popular diabetes medication metformin may lower the risk of developing pancreatic cancer, at least among women.